Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
Prostate specific antigen (PSA) testing is now a routine part of the investigation of men with suspected prostate cancer. While a very useful test it still has its problems, in particular its lack of specificity means abnormal results are often caused by benign disease. This review describes the current problems with PSA testing in prostate cancer diagnosis and highlights potential ways in which these may be reduced.
Jain
S
S
Division of Urology, University of Leicester, Leicester General Hospital, UK. sj34@le.ac.uk
Bhojwani
A G
AG
Mellon
J K
JK
D000328:Adult; D000367:Age Factors; D000368:Aged; D001706:Biopsy / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D012680:Sensitivity and Specificity; D020840:Tissue Kallikreins / Q000378:metabolism; D000514:alpha 1-Antichymotrypsin / Q000378:metabolism
D000514:alpha 1-Antichymotrypsin; D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen